Gut microbiota and inflammation.
Gut microbiota and inflammation.
复制标题
作者：
Hakansson A;Molin G
与人体胃肠道微生物区系有关的全身性和局部性炎症以及益生菌的应用是本综述的主要主题。人类胃肠道的主要分类群及其加重或抑制炎症的潜力被描述。综述的重点是益生菌的人体试验，不包括体外研究和动物实验模型。益生菌的应用包括全身免疫调节、代谢综合征、肝脏损伤、炎症性肠病、结直肠癌和放射性肠炎。当考虑到不同类型的益生菌之间的主要基因组差异时，可以预期人体对不同种类和菌株的益生菌的反应是不同的。在讨论益生菌临床试验的结果时，这一事实经常被忽视。
Systemic and local inflammation in relation to the resident microbiota of the human gastro-intestinal (GI) tract and administration of probiotics are the main themes of the present review. The dominating taxa of the human GI tract and their potential for aggravating or suppressing inflammation are described. The review focuses on human trials with probiotics and does not include in vitro studies and animal experimental models. The applications of probiotics considered are systemic immune-modulation, the metabolic syndrome, liver injury, inflammatory bowel disease, colorectal cancer and radiation-induced enteritis. When the major genomic differences between different types of probiotics are taken into account, it is to be expected that the human body can respond differently to the different species and strains of probiotics. This fact is often neglected in discussions of the outcome of clinical trials with probiotics.
登录
查看更多内容
影响因子：
3.7
作者：
Biagi E;Nylund L;Candela M;Ostan R;Bucci L;Pini E;Nikkïla J;Monti D;Satokari R;Franceschi C;Brigidi P;De Vos W
通讯作者：
De Vos W
影响因子：
2.3
作者：
Blumberg, Richard S.
通讯作者：
Blumberg, Richard S.
影响因子：
9.8
作者：
Bajaj, Jasmohan S.;Saeian, Kia;Binion, David G.
通讯作者：
Binion, David G.
影响因子：
5.9
作者：
Ahrne S;Hagslatt ML
通讯作者：
Hagslatt ML
影响因子：
3.8
作者：
Berezow AB;Ernst RK;Coats SR;Braham PH;Karimi-Naser LM;Darveau RP
通讯作者：
Darveau RP